Latest News and Press Releases

NEW YORK and LONDON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Sumitovant Biopharma Ltd., the majority shareholder of Myovant Sciences (NYSE: MYOV),  announced today that Myovant Sciences, a healthcare...

Myovant and Pfizer to jointly develop and commercialize ORGOVYX™ (relugolix) and relugolix combination tablet and share profits and expenses in the U.S. and Canada Myovant to receive an upfront...

NEW YORK, LONDON, IRVINE, Calif. & BASEL, Switzerland, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Sumitovant Biopharma Ltd., today announced that Urovant Sciences (Nasdaq: UROV), a member of the...

NEW YORK, LONDON, BASEL, Switzerland, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Sumitovant Biopharma Ltd., a majority shareholder of Myovant Sciences (NYSE: MYOV), announced today that Myovant Sciences, a...

PHILADELPHIA, PA, Oct. 13, 2020 (GLOBE NEWSWIRE) -- PHILADELPHIA, PA, October 13, 2020 – Spirovant Sciences, a gene therapy company developing treatments and cures for genetic lung diseases...

PHILADELPHIA, PA, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Spirovant Sciences, a gene therapy company developing treatments and cures for genetic lung diseases including cystic fibrosis, today announced...

PHILADELPHIA, PA, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Spirovant Sciences, a gene therapy company developing treatments and cures for genetic lung diseases including cystic fibrosis, today announced...

Cary, N.C. and Basel, Switzerland, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory...

LONDON and NEW YORK, June 22, 2020 (GLOBE NEWSWIRE) -- Sumitovant Biopharma is pleased to announce that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review, the New Drug...

LONDON and NEW YORK, June 19, 2020 (GLOBE NEWSWIRE) -- Sumitovant Biopharma Ltd. today announced that Urovant Sciences (Nasdaq: UROV), a member of the Sumitovant Biopharma family of companies, has...